Get the Stockscreener App
11.23
1.66%
-0.19
After Hours:
11.59
0.36
+3.21%
Greenwich Lifesciences Inc stock is traded at $11.23, with a volume of 58,513.
It is down -1.66% in the last 24 hours and down -9.07% over the past month.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
See More
Previous Close:
$11.42
Open:
$11.58
24h Volume:
58,513
Relative Volume:
1.00
Market Cap:
$153.07M
Revenue:
-
Net Income/Loss:
$-8.89M
P/E Ratio:
-16.04
EPS:
-0.7
Net Cash Flow:
$-6.48M
1W Performance:
+2.74%
1M Performance:
-9.07%
6M Performance:
-4.10%
1Y Performance:
-21.19%
1-Day Range:
$11.20
$11.58
1-Week Range:
$10.59
$13.00
52-Week Range:
$8.06
$15.50
Greenwich Lifesciences Inc Stock (GLSI) Company Profile
Name
Greenwich Lifesciences Inc
Sector
Industry
Phone
203-434-3290
Address
3992 BLUEBONNET DR, BUILDING 14, STAFFORD
Compare GLSI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLSI
Greenwich Lifesciences Inc
|
11.23 | 155.25M | 0 | -8.89M | -6.48M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Greenwich Lifesciences Inc Stock (GLSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-25 | Initiated | Noble Capital Markets | Outperform |
| Sep-01-21 | Initiated | H.C. Wainwright | Buy |
Greenwich Lifesciences Inc Stock (GLSI) Latest News
How sentiment analysis helps forecast Greenwich LifeSciences Inc.Quarterly Growth Report & Daily Oversold Stock Bounce Ideas - Newser
Smart tools for monitoring Greenwich LifeSciences Inc.’s price actionJuly 2025 Setups & AI Powered Market Entry Ideas - Newser
Tools to assess Greenwich LifeSciences Inc.’s risk profileJuly 2025 News Drivers & Stock Market Timing Techniques - Newser
Will Greenwich LifeSciences Inc. bounce back from current supportMarket Activity Report & Real-Time Market Trend Scan - Newser
Using Bollinger Bands to evaluate Greenwich LifeSciences Inc.2025 Price Momentum & Weekly Hot Stock Watchlists - Newser
Is Greenwich LifeSciences Inc. still worth holding after the dipJuly 2025 Update & Community Supported Trade Ideas - Newser
Measuring Greenwich LifeSciences Inc.’s beta against major indicesMarket Movement Recap & Stepwise Trade Signal Implementation - Newser
Quantitative breakdown of Greenwich LifeSciences Inc. recent moveAnalyst Upgrade & Breakout Confirmation Alerts - Newser
Is it time to cut losses on Greenwich LifeSciences Inc.Dividend Hike & Weekly Consistent Profit Watchlists - Newser
How moving averages guide Greenwich LifeSciences Inc. trading2025 Trading Recap & Verified Swing Trading Watchlists - Newser
Combining price and volume data for Greenwich LifeSciences Inc.2025 Momentum Check & Smart Swing Trading Techniques - Newser
What the charts say about Greenwich LifeSciences Inc. today2025 Market Trends & Long Hold Capital Preservation Plans - Newser
Is Greenwich LifeSciences Inc. stock reversal real or fake2025 Sector Review & Safe Entry Zone Tips - Newser
Custom strategy builders for tracking Greenwich LifeSciences Inc.2025 Sector Review & Daily Oversold Bounce Ideas - Newser
Short interest data insights for Greenwich LifeSciences Inc.Earnings Beat & Free Weekly Watchlist of Top Performers - Newser
How to track smart money flows in Greenwich LifeSciences Inc.July 2025 Levels & Real-Time Buy Signal Alerts - Newser
What to expect from Greenwich LifeSciences Inc. in the next 30 daysMarket Movers & Proven Capital Preservation Methods - Newser
Reversal indicators forming on Greenwich LifeSciences Inc. stockInflation Watch & AI Forecasted Stock Moves - Newser
Real time pattern detection on Greenwich LifeSciences Inc. stock2025 Year in Review & Daily Stock Trend Reports - Newser
Published on: 2025-09-11 23:20:16 - Newser
Analyzing net buyer seller activity in Greenwich LifeSciences Inc.Market Sentiment Summary & Technical Entry and Exit Tips - Newser
What Fibonacci levels say about Greenwich LifeSciences Inc. reboundEarnings Performance Report & Risk Controlled Swing Alerts - Newser
Sector ETF performance correlation with Greenwich LifeSciences Inc.Bond Market & Daily Technical Forecast Reports - Newser
FDA grants fast track designation to Greenwich LifeSciences’ breast cancer therapy - Investing.com India
Greenwich LifeSciences Inc. stock volume spike explainedOil Prices & Weekly Top Gainers Trade List - Newser
FDA Grants Fast Track Designation to GLSI-100 in HLA-A*02+, HER2+ Breast Cancer - OncLive
Nike, US chipmakers, Greenwich LifeSciences - TradingView
Greenwich LifeSciences jumps on FDA fast track for breast cancer therapy By Investing.com - Investing.com South Africa
Greenwich LifeSciences jumps on FDA fast track for breast cancer therapy - Investing.com Canada
Greenwich LifeSciences wins FDA Fast Track status (GLSI) - Seeking Alpha
Greenwich Lifesciences' GLSI-100 granted US FDA fast track designation - MarketScreener
Greenwich LifeSciences’ GLSI-100 Granted US FDA Fast Track Designation - GlobeNewswire
News impact scoring models applied to Greenwich LifeSciences Inc.July 2025 Drop Watch & AI Optimized Trading Strategy Guides - Newser
Should you hold or exit Greenwich LifeSciences Inc. nowPortfolio Risk Summary & Safe Entry Trade Signal Reports - Newser
Greenwich Lifesciences Inc Stock (GLSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):